Research programme: VEGF receptor inhibitors - Bayer HealthCare PharmaceuticalsAlternative Names: ZK 261991
Latest Information Update: 22 Mar 2011
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Vascular endothelial growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 29 Mar 2010 Preclinical development is ongoing in Germany
- 11 May 2007 Preclinical trials in Solid tumours in Germany (PO)